Skip to main content Back to Top


Azathioprine Tablets

Products Affected - Description

    • Azathioprine oral tablet, Roxane, 50 mg, 100 count, NDC 00054-4084-25
    • Azathioprine oral tablet, Roxane, 50 mg, unit-dose 100 count, NDC 00054-8084-25

Reason for the Shortage

    • Roxane discontinued azathioprine tablets in mid-January 2015 due to problems obtaining active ingredient.
    • Valeant acquired Salix Pharmaceuticals in April 2015.
    • Mylan could not provide a reason for the shortage.
    • Prometheus Laboratories states the reason for the shortage was increased demand.

Available Products

    • Azasan oral tablet, Valeant, 100 mg, 100 count, NDC 65649-0241-41
    • Azasan oral tablet, Valeant, 75 mg, 100 count, NDC 65649-0231-41
    • Imuran oral tablet, Prometheus Laboratories, 50 mg, 100 count, NDC 65483-0590-10
    • Azathioprine oral tablet, Mylan, 50 mg, unit-dose 50 count, NDC 51079-0620-06
    • Azathioprine oral tablet, Mylan, 50 mg, 100 count, NDC 00378-1005-01
    • Azathioprine oral tablet, Zydus, 50 mg, 100 count, NDC 68382-0003-01
    • Azathioprine oral tablet, Zydus, 50 mg, 500 count, NDC 68382-0003-05

Estimated Resupply Dates

    • All suppliers have product available.


Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 29, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.